Allergan, Inc.

Advanced Medical Optics, Inc.

Other

Iolyx Therapeutics, Inc.

Richard S Graham

Orest Olejnik

Peter G Bakhit

Joseph G Vehige

James Nienyuan Chang

Chin-Ming Chang

Bernard F Grisoni

Anuradha V Gore

Christopher E Doyle

Rhett M Schiffman

Mayssa Attar

Walter L Tien

James A Burke

Robert T Lyons

Chetan Pujara

Crystal M Cunanan

Ke Wu

Teresa H Kuan

Scott W Smith

Lakshmi Rajagopalan

Alexandra Almazan

Corine Ghosn

Eldon Quinn Farnes

Chetan P Pujara

Robert M Burk

David W Old

Wha Bin Im

Vithal J Rajadhyaksha

Kevin S Warner

R Scott Jordan

Ajay P Parashar

Sukhon Likitlersuang

Jie Shen

Devin F Welty

Eldon Q Farnes

Michael Engles

Mu-Lan Lee

Robert S Jordan

Thomas K Karami

James E Francese

Rozemarijn Verhoeven

Aileen Morgan

Kristin B Prinn

Sesha Neervannan

Kiomars Karami

Hovhannes John Gukasyan

Elizabeth W Jeffords

Daniel J Estes

Houman David Hemmati

Melissa Gulmezian

Ramakrishnan Srikumar

Jim Jiao

David A Hollander

Linda Villanueva

Kristin Prinn

David Hollander

The present invention relates to methods of treating ocular inflammatory diseases by administering ophthalmic pharmaceutical compositions of roflumilast. Administration of ophthalmic pharmaceutical compositions of roflumilast can provide significant immunomodulatory and anti-inflammatory activity relative to existing immunomodulatory, immunosuppressant, or non-steroidal anti-inflammatory therapies, including corticosteroids and antihistamines, while also providing an improved safety and convenience profile relative to one or both agents.

Methods of treating ocular inflammatory diseases

Disclosed are antiseptic compositions for disinfecting tissues, in particular for ocular use. Methods and compositions disclosed herein include sodium chlorite, optionally in combination with a surfactant.

Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity

Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity

Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.

Compositions containing alpha-2-adrenergic agonist components

Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same. 

Quaternary ammonium alkyl esters as stable prodrugs

Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.

Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers

Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.

Cyclosporin compositions

The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.

Crystalline form of cyclosporine A, methods of preparation, and methods for use thereof

The present invention provides an aqueous ophthalmic solution with an effective amount of ketorolac and carboxymethyl cellulose in an aqueous solution which provides increased visual acuity and wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Ketorolac tromethamine compositions for treating or preventing ocular pain

The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.

Compositions for delivery of therapeutics into the eyes and methods for making and using same

The invention provides ophthalmic formulations containing well-defined substituted gamma lactams. The formulations described herein are useful in treating a variety of ocular diseases related to ocular hypertension, such as for example, glaucoma.

Ophthalmic formulations containing substituted gamma lactams and methods for use thereof

A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.

Pharmaceutical compositions comprising cyclosporins

Growing community of inventors

Irvine, CA, United States of America

Richard S Graham